Sugi Predict

Sugi Predict / Compounds / SCHEMBL6370619

SCHEMBL6370619

SCHEMBL6370619

OC[C@@H](O)C1CCNCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CPN1 P15169 1/20 0.41
▸ CPB2 Q96IY4 1/20 0.41
▸ SLC6A2 P23975 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39
▸ TP53 P04637 1/20 0.34
▸ AGL P35573 1/20 0.34
▸ PMP22 Q01453 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ GMNN O75496 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ GABRA1 P14867 2/20 0.32
▸ TSHR P16473 2/20 0.32
▸ GABRG2 P18507 2/20 0.32
▸ GABRB3 P28472 2/20 0.32
▸ GABRA5 P31644 2/20 0.32
▸ GABRA3 P34903 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1693008 1.00 CPN1 (0.41) CPN1CPB2SLC6A2SLC6A4SLC6A3
SCHEMBL22066364 1.00 CPN1 (0.41) CPN1CPB2SLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL20568930 0.98 SLC6A2 (0.41) CPN1CPB2SLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL20568674 0.98 SLC6A2 (0.41) CPN1CPB2SLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL5729497 0.98 SLC6A2 (0.41) CPN1CPB2SLC6A2SLC6A4SLC6A3
SCHEMBL6488556 0.86 — —
SCHEMBL6488553 0.86 — —
Hydrochloric Acid SCHEMBL28345867 0.84 SLC6A2 (0.36) CPN1CPB2SLC6A2SLC6A4SLC6A3
SCHEMBL6371560 0.81 CPN1 (0.38) CPN1CPB2SLC6A2SLC6A4SLC6A3
SCHEMBL2246490 0.81 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4696376-A2 NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF Topadur Pharma AG (CH) 2026-02-18 — — EP disclosed
EP-3630769-B1 NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2025-07-02 — — EP disclosed
US-20240360136-A1 DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2024-10-31 — — US disclosed
CN-118063458-A Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof 托帕杜制药公司 2024-05-24 — — CN disclosed
US-11905293-B2 Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof TOPADUR PHARMA AG (CH) 2024-02-20 — — US disclosed
CN-110621676-B Dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof 托帕杜制药公司 2024-02-09 — — CN disclosed
US-20220073529-A1 DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2022-03-10 — — US disclosed
US-20220073529-A1 DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2022-03-10 — — US disclosed
US-11155558-B2 Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof TOPADUR PHARMA AG (CH) 2021-10-26 — — US disclosed
US-20200181149-A1 NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2020-06-11 — — US disclosed
WO-2020109354-A1 NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2020-06-04 — — WO disclosed
CN-110621676-A Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof 托帕杜制药公司 2019-12-27 — — CN disclosed
US-20050096278-A1 Antibacterial agents ELLSWORTH EDMUND L (US) 2005-05-05 — — US disclosed
WO-2005026145-A2 QUINOLONE ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2005-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073529-A1 DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF PDE5A, PDE1A, PDE2A CPN1 1846/4885CPB2 651/4885SLC6A2 762/4885
US-11155558-B2 Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof PDE7A, GNAO1, PDE3A CPN1 510/4885CPB2 733/4885SLC6A2 1814/4885
US-20200181149-A1 NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF PDE7A, PDE3A, PDE9A CPN1 435/4885CPB2 796/4885SLC6A2 2058/4885
US-11905293-B2 Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof PDE5A, PDE1A, PDE2A CPN1 1846/4885CPB2 651/4885SLC6A2 762/4885
US-20240360136-A1 DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF PDE5A, PDE1A, PDE2A CPN1 1846/4885CPB2 651/4885SLC6A2 762/4885
US-20050096278-A1 Antibacterial agents MRPL21, FBL, SDHA CPN1 4032/4885CPB2 1980/4885SLC6A2 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.